New Diels-Alder adducts and derivatives
The disadvantages of existing PTAD were solved and high yields were achieved by forming a new Diels-Aldega compound with cholesterite-5,7,24-triene-3-ol and new diene affinities. 25-hydroxy-7-dehydrocholesterol was obtained, which improved the production efficiency of vitamin synthesis intermediates.
Patent Information
- Application Number
- CN202011501667.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-19
- Filing Date
- 2020-12-18
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2040-12-18
AI Technical Summary
In the existing Diels-Alder reaction, 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) or its dehydrocholesterol adduct has certain disadvantages. An alternative Diels-Aldega compound is needed for use in vitamin synthesis.
New Diels-Aldega compound is formed by cholesteric-5,7,24-triene-3-ol with new diene affinite, using specific reaction conditions and reagents such as 1,3, 5-Trichloro-1,3,5-Triazinane-2,4,6-trione and oxidizing agents to produce 25-hydroxy-7-dehydrocholesterol in high yields.
The new Diels-Aldega compound and 25-hydroxy-7-dehydrocholesterol were achieved in high yields, providing an effective method to replace PTAD and improving the intermediate generation efficiency in vitamin synthesis.
Smart Images

Figure CN113004367B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the Diels-Alder products of cholesta-5,7,24-trien-3-ol and derivatives, and in particular to the formation of 25-hydroxy-7-dehydrocholesterol. Background Art
[0002] Cholesta-5,7,24-trien-3-ol and its derivatives, especially 25-hydroxy-7-dehydrocholesterol, are important intermediates in the synthesis of vitamins.
[0003] The formation of Diels-Alder adducts is one of the essential reaction steps in one of the most important syntheses.
[0004] In particular, 4-phenyl-1,2,4-triazolidine-3,5-dione (PTAD) is a very commonly used dienophile for the Diels-Alder reaction, since it is one of the strongest known dienophiles. However, PTAD or its adduct with dehydrocholesterol, respectively, has certain disadvantages.
[0005] Therefore, there is a need for alternative Diels-Alder adducts which can be used in vitamin synthesis. Summary of the invention
[0006] The problem underlying the present invention was therefore to provide novel Diels-Alder adducts suitable for cholest-5,7,24-trien-3-ols.
[0007] Surprisingly, it has been found that novel Diels-Alder adducts can be formed from cholesta-5,7,24-trien-3-ol as diene and novel dienophiles.
[0008] These Diels-Alder adducts can be obtained in high yields and in an efficient manner. It was also shown that other intermediates as well as 25-hydroxy-7-dehydrocholesterol can be obtained efficiently in high yields.
[0009] Further aspects of the invention are the subject matter of further independent claims. Particularly preferred embodiments are the subject matter of the dependent claims. DETAILED DESCRIPTION
[0010] In a first aspect, the present invention relates to compounds of formula (I)
[0011]
[0012] It is characterized in that X represents NR 1 or C(R 1 )2, where R 1 represents methyl or ethyl or propyl or butyl; and
[0013] R represents H or acyl, preferably H.
[0014] For the sake of clarity, some terms used in this document are defined below:
[0015] In this document, “C x-y An "-alkyl" group is an alkyl group containing from x to y carbon atoms, i.e., for example, C 1-3 -Alkyl groups are alkyl groups containing 1 to 3 carbon atoms. Alkyl groups can be straight or branched. For example, -CH(CH3)-CH2-CH3 is considered a C4-alkyl group. Thus, "propyl" can be "n-propyl" or "iso-propyl" (=isopropyl). Similarly, "butyl" can be "n-butyl" or "isobutyl" or "sec-butyl" or "tert-butyl".
[0016] In this document, the term "independently of one another" means that in the context of a substituent, a fragment or a group, the specified substituent, a fragment or a group can occur simultaneously in the same molecule with different meanings.
[0017] In case the same symbol or radical designation is present in a plurality of formulae, in this document the definition of said radical or symbol in the context of one specific formula also applies to the other formulae containing the same said designation.
[0018] The expression "manufacturing process" is a synonym for "production process" or "production method" and can be used interchangeably with each other.
[0019] In a preferred embodiment of the present invention, X=NR 1 , where R 1 It represents methyl, ethyl or isopropyl.
[0020] In another preferred embodiment of the present invention, X=C(R 1 )2, where R 1 It represents a methyl or ethyl group.
[0021] The compound of formula (I) has a substituent R which represents H or an acyl group, preferably H.
[0022] In the case where R represents an acyl group, the compounds of formula (I) can be easily synthesized by reaction of the corresponding acyl halides such as acetyl chloride or benzoyl chloride, or the anhydrides of the corresponding carboxylic acids, for example acetic anhydride or benzoic anhydride, in particular from the corresponding alcohols of formula (I) with R = H. Such esterification reactions and the corresponding reagents and conditions are known to those skilled in the art. The embodiment with R = acyl has a particularly high storage stability.
[0023] Preferred acyl groups R are acetyl or benzoyl:
[0024]
[0025] However, it is preferred that R represents H.
[0026] The compound of formula (I) can be synthesized from the compounds of formula (XI) and (XII).
[0027] Therefore, in another aspect, the invention relates to a process for preparing a compound of formula (I) by reacting a compound of formula (XI) with a compound of formula (XII).
[0028]
[0029] Substituents X and R are as described above for the compounds of formula (I).
[0030] The reaction between compounds of formula (XII) and (XI) is a type of Diels-Alder reaction. Thus, the compound of formula (I) can be viewed as a Diels-Alder adduct of a compound of formula (XI) ("diene") and a compound of formula (XII) ("dienophile").
[0031] In the case where R represents an acyl group, compounds of the formula (XI) can be easily synthesized from the corresponding alcohols of the formula (XI) with R═H, in particular by reaction with the corresponding acyl halides, such as acetyl chloride or benzoyl chloride, or the anhydrides of the corresponding carboxylic acids, for example acetic anhydride or benzoic anhydride. Such esterification reactions and the corresponding reagents and conditions are known to those skilled in the art. The embodiment with R═acyl has a particularly high storage stability.
[0032] The compound of formula (XI) is a sterol 5,7-diene. Preferably it is cholesta-5,7,24-trien-3-ol. These compounds are known to the person skilled in the art and can be obtained commercially from different sources.
[0033] Formation of the compound of formula (XII)
[0034] The compound of formula (XII) can be prepared by oxidation of a compound of formula (XIII) or a salt thereof with an oxidizing agent (Ox), in particular by oxidation of a compound of formula (XIV).
[0035]
[0036] 1,3,5-Trichloro-1,3,5-triazinane-2,4,6-trione of formula (XIV) is known to those skilled in the art and is readily available from different sources.
[0037] There are other oxidants that can be used. In particular, bleach (NaOCl) is a suitable oxidant. However, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione is the preferred oxidant.
[0038] The reaction usually takes place in a solvent under an inert gas. Preferably, the reaction is carried out under argon or nitrogen. The solvent that can be used for the reaction should be such that it is inert to the substances in the reaction mixture. Usually, this is an organic solvent selected from hydrocarbons and esters. It has been observed that alkyl acetates, in particular ethyl acetate, are particularly suitable for use as solvents. The reaction is usually carried out at a temperature below 40°C, in particular at a temperature between 0°C and 30°C, more preferably at a temperature between 20°C and 28°C.
[0039] Preferably, the 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione of formula (XIV) is added slowly to the compound of formula (XIII).
[0040] The reaction can be carried out in the presence or absence of a basic substance. The use of a base is advantageous because the HCl formed during the reaction can thereby be easily captured. Tertiary amines are particularly preferred as bases. A particularly preferred base is pyridine.
[0041] The formation of the compound of formula (XII) is indicated by a color change.
[0042] In one embodiment, the substituent X in the compound of formula (XII) or (XIII) is respectively C(R 1 )2. In this embodiment, the compound of formula (XIII) can be prepared from hydrazine and the corresponding 2,2-dialkylmalonate and a base such as sodium ethoxide. In this embodiment, R 1 Preferably, it represents a methyl group or an ethyl group.
[0043] In another embodiment, the substituent X in the compound of formula (XII) or (XIII) is NR 1 :
[0044]
[0045] The compound of formula (XIII-A) or its salt (XIII-B) can be obtained by cyclizing the compound of formula (XV) in the presence of a base YOH;
[0046]
[0047]
[0048] wherein Y represents an alkali metal and Z represents H or Y;
[0049] Where R 1 and R" independently represent methyl or ethyl or isopropyl or butyl.
[0050] The compound of formula (XIII-B) is in equilibrium with the enol tautomer:
[0051]
[0052] The cyclization reaction is very efficient.
[0053] Y is preferably an alkali metal, preferably K or Na, most preferably Na.
[0054] Preferably, the cyclization is preferably carried out in the presence of an organic solvent (S) that forms an azeotrope with water. The solvent is preferably ethanol. More preferably, the cyclization reaction is carried out at an elevated temperature, in particular at the reflux temperature of the solvent. In addition, it is carried out that during the cyclization reaction, the azeotrope of the solvent (S) and water is removed from the reaction mixture by distillation. During the reaction, the compound of formula (XIII-B) is usually precipitated and can be easily filtered out. The molar ratio of the base YOH to the compound of formula (XV) is preferably at least 1, usually at least 1.2. When the ratio is significantly increased from 1, the amount of the disalt, i.e., the formula (XIII-B) in which Z=Y, increases significantly. After acidifying or separating the salt (XIII-B) formed at the end of the cyclization reaction, the compound (XIII-A), alkyl urazole, can be obtained. However, as mentioned above, its salt (XIII-B) can also be used for oxidation to produce a compound of formula (XII-A), which is wherein X represents NR 1 A compound of formula (XII):
[0055]
[0056] The compound of formula (XV) can be obtained from an alkylamine of formula (XVIII) and a 1-alkyl 2-arylhydrazine-1,2-dicarboxylate of formula (XVII):
[0057]
[0058] Substituent R a , R b , R c , R d and R e Independently of each other, it represents H or C 1-4 -alkyl.
[0059] 1-Alkyl 2-aryl hydrazine-1,2-dicarboxylates of formula (XVII) can be formed by reacting an alkyl hydrazinocarboxylate of formula (XIX) with an aryl chloroformate of formula (XX).
[0060]
[0061] Preferably, R a , R b , R c , R d and Re represents H or methyl or ethyl, more preferably H or methyl. Preferably, the substituent R a , R b , R c , R d and R e No more than two of them represent C 1-4 -alkyl.
[0062] R a , R b , R c , R d and R e The preferred combination is:
[0063] -R a = methyl or ethyl, preferably methyl, and R b =R c =R d =R e =H
[0064] -R b = methyl or ethyl, preferably methyl, and R a =R c =R d =R e =H
[0065] -R c = methyl or ethyl, preferably methyl, and R a =R b =R d =R e =H
[0066] -R a =R e = methyl or ethyl, preferably methyl, and R b =R c =R d =H
[0067] -R b =R d = methyl or ethyl, preferably methyl, and R a =R c =R e =H
[0068] -R a =R b =R c =R d =R e =H
[0069] In the most preferred embodiment, all substituents R a , R b , Rc , R d and R e represents H, i.e. the preferred aryl chloroformate is phenyl chloroformate.
[0070] The reaction of the alkylhydrazinecarboxylate of formula (XIX) to the compound of formula (XV) is preferably carried out in a one-pot reaction, wherein the intermediate 1-alkyl 2-arylhydrazine-1,2-dicarboxylate of formula (XVII) is not isolated, in particular in the alkyl acetate of formula CH3COOR"'. In which R"' represents methyl or ethyl or propyl or butyl, in particular ethyl or propyl or butyl, preferably butyl or isopropyl.
[0071] Figure 2 The various reactions involved in forming compound (XII-A) of formula (XIII-B) or (XIII-A), respectively, as discussed above are shown schematically.
[0072] Formation of the compound of formula (I)
[0073] The compound of formula (XI) is reacted with a compound of formula (XII) to produce a Diels-Alder adduct of formula (I).
[0074] It is suitable to carry out the reaction in a solvent under an inert gas. Preferably, the reaction is carried out under argon or nitrogen.
[0075] The reaction of the compound of formula (XI) with the compound of formula (XII) to produce the Diels-Alder adduct of formula (I) is usually carried out at ambient temperature and pressure. In addition, the reaction is preferably carried out in an inert solvent. Preferably, the compound of formula (XII) is preferably added to the compound of formula (XI) in small batches and under stirring.
[0076] During the reaction, the Diels-Alder adduct of formula (I) is formed as a solid.
[0077] Preferably, the compound of formula (XII) is generated in situ from the compound of formula (XIII). Basically, the reaction steps a) and b) of the formation of the compound of formula (XII) can take place in situ, i.e., the reaction of the compounds of formula (XIII), (XIV) and (XII) forms a reaction mixture. In this variant, the dienophile, i.e., the compound of formula (XII), is formed in situ and reacts directly with the diene, i.e., the compound of formula (XI), to produce the corresponding Diels-Alder adduct of formula (I). However, it is advantageous when the formation of the compound of formula (XII) is carried out separately, i.e., the formation of the compound of formula (XII) is carried out in the absence of the sterol 5,7-diene of formula (XI).
[0078] Typically, the compound of formula (I) is purified in a further step. Particularly suitable purification methods are extraction or recrystallization / reprecipitation. Preferably, an aqueous alkaline phase is added to the reaction mixture.
[0079] Such an alkaline aqueous phase is generally a solution of an inorganic or organic base. Weak bases are preferred. In particular, the alkaline aqueous phase is a solution of a bicarbonate, preferably sodium bicarbonate (sodium bicarbonate) in water.
[0080] Furthermore, it is preferred that after adding the alkaline aqueous phase, extraction is performed with a polar organic solvent to obtain a polar solvent-based extract.
[0081] Suitable polar organic solvents for the extraction are preferably esters, especially ethyl acetate.
[0082] Formation of the compound of formula (II)
[0083] The compounds of the formula (I) can be reacted further, in particular to give epoxides of the formula (II).
[0084] Therefore, in another aspect, the present invention relates to a process for preparing a compound of formula (II)
[0085]
[0086] Comprising the reaction step a)
[0087] a) epoxidizing the compound of formula (I) by an epoxidizing agent (EPA)
[0088]
[0089] The substituents R and X have been discussed in detail above.
[0090] The compounds of formula (II) are preferably prepared as described in detail above.
[0091] The epoxidation of step a using an epoxidizing agent (EPA) is known to the person skilled in the art. Particularly suitable epoxidizing agents are peroxy compounds, in particular hydroperoxides, or peroxycarboxylic acids or esters of peroxycarboxylic acids, in particular perbenzoic acid or 3-chlorobenzoperoxic acid.
[0092] The compounds of formula (II) are new and inventive.
[0093] Therefore, in another aspect, the invention relates to compounds of formula (I).
[0094]
[0095] Formation of the compound of formula (III)
[0096] The compounds of the formula (II) can be reacted further, in particular to give alcohols of the formula (III).
[0097] Therefore, in another aspect, the present invention relates to a process for preparing a compound of formula (III)
[0098]
[0099] comprising reaction step b)
[0100] b) reducing the compound of formula (II) with a reducing agent (Red) to obtain a compound of formula (III)
[0101]
[0102] The substituents R and X have been discussed in detail above.
[0103] The compounds of formula (III) are preferably prepared as described in detail above.
[0104] The reduction in step b) can be carried out using a suitable reducing agent (Red). In step b), on the one hand, the epoxy groups are converted into alcohol groups and on the other hand, a retro-Diels-Alder reaction is carried out.
[0105] Suitable reducing agents are, in particular, complex hydrides, especially LiAlH4.
[0106] The compound of formula (III) is 25-hydroxy-7-dehydrocholesterol (=HyDHC) and is a precursor of 25-hydroxy-vitamin D3 (=Calcidiol).
[0107] Therefore, preferably, prior to step b), the process for preparing a compound of formula (II) as described above is carried out to provide a compound of formula (II).
[0108] Figure 1 An overview of the individual reactions most relevant to the present invention is shown schematically.
[0109] In a first aspect, a process for preparing a compound of formula (I) is shown.
[0110] In another aspect, a process for preparing a compound of formula (II) from a compound of formula (I) comprising an epoxidation step a) is shown.
[0111] In another aspect, a method of preparing a compound of formula (III) by reducing a compound of formula (II) is shown.
[0112] And finally, it shows the formation of a compound of formula (XII) by oxidation of a compound of formula (XIII) or a salt thereof.
[0113] It should be mentioned that for the substituent R in formula (I), (II) and (III), when R is different from H, it is preferably prepared in the following manner:
[0114] In the case where R represents an acyl group in formula (I) or (II) or (III), the compound of formula (I) can be easily synthesized by reaction of the corresponding acyl halide, for example acetyl chloride or benzoyl chloride, or the corresponding carboxylic acid anhydride, for example acetic anhydride or benzoic anhydride, in particular from the alcohol of the respective formula (I) or (II) or (III) with R=H. Such esterification reactions and the corresponding reagents and conditions are known to those skilled in the art. The embodiment with R=acyl has a particularly high storage stability.
[0115] The acyl group R can also be easily removed by acid or basic hydrolysis to form the corresponding alcohol (R═H) of the formula (I), (II) or (III).
[0116] Example
[0117] The present invention is further illustrated by the following experiments.
[0118] Experimental part A: Synthesis of dienophile (DP)
[0119] Synthesis of Methyluracil Monosodium Salt: (DP-M)
[0120] A 250 mL round-bottom flask was charged with 9.0 g (0.23 mol, 1.2 eq) of solid NaOH and 103 g of methanol. After dissolution, 30.0 g (0.19 mol, 1.0 eq) of ethyl 2-(methylcarbamoyl)hydrazine-1-carboxylate was added, followed by 16 g of methanol. The reaction mixture was refluxed for 3.5 h until the conversion reached 99%. The light yellow suspension was cooled to 5 ° C and the product was filtered. After washing the filter cake with cold methanol (2 times, 24 g), the product was dried (40 ° C, 1 mbar) to obtain 21.9 g of methyl-urea monosodium salt (98.5% w / w, 83% yield), and characterized by NMR:
[0121] 1 H-NMR (300MHz, D2O): δ (ppm) = 3.01 (s, 3H)
[0122] 13 C-NMR (75MHz, D2O): δ (ppm) = 24.9, 157.7.
[0123] Synthesis of Ethyl Urea Monosodium Salt: (DP-E)
[0124] Ethyl urazole monosodium salt was prepared by using the procedure described above for DP-M except that an equimolar amount of ethyl 2-(ethylcarbamoyl)hydrazine-1-carboxylate was used in place of ethyl 2-(methylcarbamoyl)hydrazine-1-carboxylate.
[0125] 1 H-NMR (300MHz, D2O): (ppm) = 1.17 (t, 3H, J = 7.25Hz), 3.50 (q, 2H, J = 7.25Hz)
[0126] 13 C-NMR (75MHz, D2O): (ppm) = 13.3, 33.8, 156.5.
[0127] Synthesis of isopropyl uridine monosodium salt: (DP-IP)
[0128] Isopropyl urazole monosodium salt was prepared by using the procedure described above for DP-M except that an equimolar amount of ethyl 2-(isopropylcarbamoyl)hydrazine-1-carboxylate was used in place of ethyl 2-(methylcarbamoyl)hydrazine-1-carboxylate.
[0129] 1 H-NMR (300MHz, D2O): δ (ppm) = 1.40 (d, 6H, J = 6.99Hz), 4.16 (h, 1H, J = 6.99Hz)
[0130] 13 C-NMR (75MHz, D2O): δ (ppm) = 19.3, 43.5, 156.5.
[0131] Synthesis of 4,4-diethylpyrazolidine-3,5-dione (DP1)
[0132] Diethyl 2,2-diethylmalonate (10.09 g, 46.2 mmol) and sodium ethoxide (44.1 ml, 118 mmol) in ethanol were mixed. Subsequently, a 1 M hydrazine (43.9 ml, 43.9 mmol) solution in tetrahydrofuran (THF) was slowly added and then refluxed for 4 h. The reaction mixture was evaporated. The residue was dissolved in water (24 ml) and extracted with methyl tert-butyl ether (MTBE) (3×12 ml). The aqueous phase was acidified with 25% aqueous hydrochloric acid and the resulting precipitate was filtered. The filter cake was washed with ethanol (3×5 ml) and dried in vacuo to obtain 10.15 g (96.2%) of 4,4-diethylpyrazolidine-3,5-dione (DP1) in a yield of 67.9%, and was purified by 1 H-NMR and LC-MS characterization:
[0133] 1H-NMR: (300MHz, DMSO-d6): δ (ppm) = 0.74 (t, 6H), 1.55 (q, 4H, J = 7.3Hz), 10.50 (s, 2H).
[0134] LC-MS m / z:157(M + +H); 313(2M + +H).
[0135] Experimental Part B: Synthesis of Diels-Alder Adducts
[0136] General steps for using DP-M, DP-E and DP-IP
[0137] In a flask, 6.75 mmol of the dienophile of Table 1 prepared as above was suspended in ethyl acetate (26.1 ml) under argon and a solution of HCl in ethyl acetate (7 ml, 7 mmol, 1 M) was slowly added. 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione (0.61 g, 2.37 mmol) in ethyl acetate (1.7 ml) was added dropwise over 10 min. The white suspension immediately turned pink and was stirred for 30 min. The suspension was slowly (over 5 min) added to a flask under argon, which had a solution of 27.5 g of cholester-5,7,24-triene-3-ol (3.38 mmol) in heptane / ethyl acetate (70 vol / 30 vol). The reaction mixture was stirred for 1 h. All volatiles were removed in vacuo and the residue was purified by column chromatography. The mixture was prepared as follows.
[0138] The Diels-Alder adducts were isolated in the yields shown in Table 1.
[0139] Diels-Alder adduct Dienophiles used Yield [%] DAA-M DP-M 91 DAA-E DP-E 13 DAA-IP DP-IP 92
[0140] Table 1. Preparation of Diels-Alder adducts
[0141] The corresponding Diels-Alder adducts are obtained by 1 H-NMR, 13 C-NMR and LC-MS Characterization:
[0142] DAA-M
[0143] 1 H-NMR (300MHz, CDCl3): δ (ppm):
[0144] 0.77(s,3H,C(18)H3),0.90-0.97(m,6H,C(21)H3),1.02-1.58(m,11H),1.60(s,3H,CH3),1.61–1.65(m, 1H),1.68(s,3H,CH3),1.70–2.11(m,8H),2.25(dd,1H,J=6.59,6.40Hz,11.87,12.06Hz,C(9)H),2.50(m, 1H,C(4)H2),2.95(s,3H,NCH3),3.12(dd,1H,J=3.87Hz,13.85HzC(4)H2),4.39(m,1H,C(3)H),5.08(br.t ,1H,J=7.16,6.97Hz,C(24)H),6.15(d,1H,J=8.29Hz,C(6)H or C(7)H),6.32(d,1H,J=8.29Hz,C(6)H or C(7)H
[0145] 13 C-NMR (75MHz, CDCl3): δ (ppm):
[0146] 13.0(CH or CH3),17.6(CH or CH3),17.7(CH or CH3),18.9(CH or CH3),22.4(CH2),23.2(CH2),24.6(CH2),25.0(CH or CH3),25.8(CH or CH3),27.5(CH2),29.1(CH2),34.2(CH2),34.7(CH2),35.1(CH or CH3),35.8(CH2),38.2(CH2),41.1(quart.C),44.0 (quart.C),49.3(CH or CH3),52.9(CH or CH3),55.1(CH or CH3),64.8(quart.C),65.5(quart.C),67.1(C(3)H),125.0(C(6)H or C(7)H or C(24)H),128.8(C(6)H or C(7)H or C(24)H),131.2(C(25)),135.6(C(6)H or C(7)H or C(24)H),147.8(CO),150.4(CO).
[0147] LC-MS(ES)m / z:
[0148] 498[M + +3H],497[M + +2H],496[M + +H],479[M ++2H-H2O],381[M + +1H-dienophile],364[M + +2H-H2O-dienophile],363[M + +2H-H2O-dienophile.
[0149] DAA-E
[0150] 1 H-NMR (300MHz, CDCl3): δ (ppm):
[0151] 0.78(s,3H,C(18)H3),0.93(s,3H,CH3)0.95(d,3H,J=6.59Hz,C(21)H3),1.00-1.16(m,2H),1.20(t,3H,J=7.16Hz,N CH3CH3),1.24–1.58(m,10H),1.60(s,3H,CH3),1.69(s,3H,CH3),1.72–2.12(m,8H),2.25(dd,1H,J=6.36,6.57Hz,11 .97,12.18Hz,C(9)H),2.52(m,1H,C(4)H2),3.12(dd,1H,J=3.84Hz,13.92HzC(4)H2),3.47(m.2H,NCH2),4.41(m,1H, C(3)H),5.09(br.t,1H,J=6.99,C(24)H),6.14(d,1H,J=8.30Hz,C(6)H or C(7)H),6.32(d,1H,J=8.30Hz,C(6)H or C(7)H)
[0152] 13 C-NMR (75MHz, CDCl3): δ (ppm):
[0153] 12.9(CH or CH3),13.5(CH or CH3),17.5(CH or CH3),17.7(CH or CH3),18.9(CH or CH3),22.4(CH2),23.3(CH2),23.3(CH2),24.6(CH2),25.7(CH or CH3),27.5(CH2),29.1(CH2),34.2(CH2),34.7(CH2),35.1(CH or CH3),35.8(CH2),38.2(CH2),41.0(quart.C) ,44.0(quart.C),49.3(CH or CH3),52.8(CH or CH3),55.0(CH or CH3),64.7(quart.C),65.4(quart.C),67.2(C(3)H),125.0(C(6)H or C(7)H or C(24)H),128.8(C(6)H or C(7)H or C(24)H),131.1(C(25)),135.4(C(6)H or C(7)H or C(24)H),147.6(CO),150.2(CO).
[0154] LC-MS(ES)m / z:
[0155] 511[M + +2H],510[M + +H],493[M + +2H-H2O],364[M + +2H-H2O-dienophile],363[M + +2H-H2O-dienophile].
[0156] DAA-IP
[0157] 1 H-NMR (300MHz, CDCl3): δ (ppm):
[0158] 0.78(s,3H,C(18)H3),0.92(s,3H,CH3)0.95(d,3H,J=6.40Hz,C(21)H3),1.01-1.3 3(m,5H),1.38(d,6H,J=6.78Hz,NCH(CH3)2),1.43–1.58(m,4H),1.60(s,3H,CH3), 1.62–1.66(m,2H),1.69(s,3H,CH3),1.73–2.12(m,9H),2.25(dd,1H,J=6.22,6.40 Hz,12.24,12.06Hz,C(9)H),2.52(m,1H,C(4)H2),3.12(dd,1H,J=4.71Hz,13.94Hz C(4)H2),4.21(spt,1H,J=6.97Hz,NCH),4.41(m,1H,C(3)H),5.09(tt,1H,J=1.32Hz,J=7.16 ,6.97Hz,C(24)H),6.14(d,1H,J=8.29Hz,C(6)H or C(7)H),6.32(d,1H,J=8.29Hz,C(6)H or C(7)H
[0159] 13 C-NMR (75MHz, CDCl3): δ (ppm):
[0160] 13.0(CH or CH3),17.6(CH or CH3),17.7(CH or CH3),18.9(CH or CH3),19.7(CH or CH3),19.8(CH or CH3),22.4(CH2),23.4(CH2),24.6(CH2),25.8(CH or CH3),27.5(CH2),29.1(CH2),34.2(CH2),34.7(CH2),35.1(CH or CH3),35.8(CH2),38.2(CH2),41.1(quart.C),44.0 (quart.C),44.0(CH or CH3),49.3(CH or CH3),52.8(CH or CH3),55.0(CH or CH3),64.7(quart.C),65.4(quart.C),67.2(C(3)H),125.0(C(6)H or C(7)H or C(24)H),128.8(C(6)H or C(7)H or C(24)H),131.2(C(25)),135.4(C(6)H or C(7)H or C(24)H),147.5(CO),150.1(CO).
[0161] LC-MS(ES)m / z:
[0162] 525[M + +2H],524[M + +H],507[M + +2H-H2O],364[M + +2H-H2O-dienophile],363[M + +2H-H2O-dienophile].
[0163] Diels-Adams reaction of cholesta-5,7,24-trien-3-ol and 4,4-diethylpyrazolidine-3,5-dione (DAA-DP1) Alder reaction
[0164] 4,4-diethylpyrazolidine-3,5-dione (DP1) (725mg, 4.43mmol) prepared as described above is suspended in ethyl acetate (23.5ml). 1,3,5-trichloro-1,3,5-triazine-2,4,6-trione (0.364g, 1.41mmol) dissolved in ethyl acetate (23.5ml) is slowly added. The suspension immediately turns blue and is stirred for 30min. The suspension is filtered. The solution is slowly added to a flask with a solution of 40g cholesteryl-5,7,24-triene-3-ol (4.00mmol) in heptane / ethyl acetate (70vol / 30vol) under argon.
[0165] The reaction mixture was stirred at 40°C for 3h. Water (50ml) was added and the reaction mixture was stirred at 23°C for 60min. The organic phase of the reaction mixture was extracted with water (2×50ml) and saturated aqueous NaCl solution (1×50ml). The aqueous layer was extracted with ethyl acetate (3×50ml). The organic solutions were combined and washed with saturated aqueous NaCl solution (3×50ml). The organic phase was dried over Na2SO4, filtered, and all volatiles were removed in vacuo (50°C, 30mbar). The residue (5.9g) was suspended in acetone (10ml) and filtered through a sinter funnel. The filter cake was washed twice with the filtrate and three times with acetone (3×2ml). The filter cake was dried at 50°C and 30mbar. The Diels-Alder adduct DAA-DP1 (2.15g, 74%) was isolated in a yield of 73%. The Diels-Alder adduct was obtained by 1 H-NMR, 13 C-NMR and LC-MS Characterization:
[0166] 1 H-NMR (300MHz, CDCl3): δ (ppm):
[0167] 0.67(t,3H,J=7.35Hz,CH2CH3),0.78(s,3H,C(18)H3),0.88(t,3H,J=7.35,7.53Hz,CH2CH3),0.92-0.97(m,6H,CH3 ),1.01-1.57(m,10H),1.60(s,3H,CH3),1.61–1.67(m,5H),1.69(s,3H,CH3),1.70–2.14(m,9H),2.29(m,1H,C(4)H ),2.58(m,1H,J=6.40,12.24Hz,C(9)H2),3.21(dd,1H,J=4.14,4.33Hz,13.75,13.94Hz,C(4)H2),4.36(m,1H,C(3) H),5.09(br.t,1H,J=6.97Hz,C(24)H),6.17(d,1H,J=8.29Hz,C(6)H or C(7)H),6.33(d,1H,J=8.29Hz,C(6)H or C(7)H);
[0168] 13 C-NMR (75MHz, CDCl3): δ (ppm):
[0169] 8.9(CH2CH3),9.7(CH2CH3),12.8(CH or CH3),17.5(CH or CH3),17.7(CH or CH3),18.9(CH or CH3),22.6(CH2),23.7(CH2),24.6(CH2),25.7(CH or CH3),27.5(CH2),28.8(CH2CH3),29.9(CH2),34.3(CH2),34.9(CH2),35.1(CH or CH3),35.8(CH2),38.3(CH2),41.1(quart.C ),43.9(quart.C),49.0(CH or CH3),52.9(CH or CH3),55.3(CH or CH3),58.4(COCCO),64.6(quart.C),65.9(quart.C),67.8(C(3)H),125.0(C(6)H or C(7)H or C(24)H),128.0(C(6)H or C(7)H or C(24)H),131.1(C(25)),135.8(C(6)H or C(7)H or C(24)H),164.6(CO),168.9(CO).
[0170] LC-MS(ES)m / z:
[0171] 537[M ++H],364[M + -2H-H2O-dienophile],363[M + -3H-H2O-dienophile].
[0172] Experimental Section C: Synthesis of Epoxidized Diels-Alder Adducts
[0173] General Procedures for Using DAA-M, DAA-E, and DAA-IP
[0174] 3.3 mmol of Diels-Alder adduct given in Table 2 and toluene (26.3 ml) were charged into a 100 ml 3-necked flask. 3-Chlorobenzene peroxyacid (2.4 g, 6.27 mmol) in toluene (17.5 ml) was slowly added to the reaction mixture. The suspension became a solution. The reaction mixture was stirred at 23° C. for 1.5 h. Sodium sulfite (1.5 g, 11.9 mmol) and sodium carbonate (1.3 g, 11.9 mmol) in 25 ml of water were added over 50 min. The reaction mixture was stirred at 23° C. for 2 h. After phase separation, the organic phase was washed with 5% aqueous sodium carbonate solution, and the organic phase was dried over Na2SO4, filtered, and all volatiles were removed in vacuo. The Diels-Alder adduct was isolated in the yield given in Table 2.
[0175]
[0176] Table 2. Epoxidized Diels-Alder adducts obtained from Diels-Alder adducts.
[0177] Each epoxidized Diels-Alder adduct was prepared by 1 H-NMR, 13 C-NMR and LC-MS Characterization:
[0178] EP-DAA-M
[0179] 1 H-NMR (300MHz, CDCl3): δ (ppm):
[0180] 0.78(s,3H,C(18)H3),0.92(s,3H,CH3)0.96(d,3H,J=6.40Hz,C(21)H3),1.07-1.23(m,4H),1.26(s,3H,CH3) ,1.30(s,3H,CH3),1.32–2.12(m,18H),2.25(dd,1H,J=6.40,6.59Hz,11.87,12.06Hz,C(9)H),2.53(m,1H,C( 4)H2),2.68(br.t,J=4.52,6.03Hz,1H,C(24)H),2.94(s,1H,NCH3)3.12(dd,1H,J=3.77,3.96Hz,13.94,14.7 5HzC(4)H2), 4.38(m,1H,C(3)H), 6.14(d,1H,J=8.29Hz, C(6)H or C(7)H), 6.31(d,1H,J=8.29Hz, C(6)H or C(7)H);
[0181] 13 C-NMR (75MHz, CDCl3): δ (ppm):
[0182] 13.0(CH or CH3),17.6(CH or CH3)18.7(CH or CH3),18.9(CH or CH3),25.0(CH2),25.0(CH2),25.5(CH or CH3),27.5(CH2),29.1(CH2),32.2(CH2),32.4(CH2),34.2(CH2),34.7(CH2),35.2(CH or CH3),38.2(CH2),41.0(quart.C),44.0(q uart.C), 49.3(CH or CH3), 52.9(CH or CH3), 55.0(CH or CH3), 58.2(quart.C), 58.4(quart.C), 64.6(CH or CH3), 64.7(quart.C), 65.4(quart.C), 67.0(C(3)H), 128.7(C(6)H or C(7)H), 135.6(C(6)H or C(7)H), 147.82(CO), 150.4(CO).
[0183] LC-MS(ES)m / z:
[0184] 512[M + +H],494[M + +H-H2O],380[M + +2H-H2O-dienophile],379M ++1H-H2O-dienophile]
[0185] EP-DAA-E
[0186] 1 H-NMR (300MHz, CDCl3): δ (ppm):
[0187] 0.80(s,3H,C(18)H3),0.94(s,3H,CH3)0.96(d,3H,J=6.40Hz,C(21)H3),1.20 (t,3H,J=7.16Hz,NCH2CH3),1.27(s,3H,CH3),1.32(s,3H,CH3),1.34–2.11(m, 20H),2.26(dd,1H,J=6.22,6.78Hz,11.87,12.43Hz,C(9)H),2.54(m,1H,C(4) H2),2.69(br.t,J=4.14,6.03Hz,1H,C(24)H),3.13(dd,1H,J=4.52Hz,13.75Hz C(4)H2), 3.49(m.2H,NCH2), 4.42(m,1H,C(3)H), 6.16(d,1H,J=8.29Hz,C(6)H or C(7)H), 6.33(d,1H,J=8.29Hz,C(6)H or C(7)H
[0188] 13 C-NMR (75MHz, CDCl3): δ (ppm):
[0189] 13.0(CH or CH3),13.5(CH or CH3),17.5(CH or CH3),17.6(CH or CH3),19.0(CH or CH3),22.4(CH2),23.3(CH2),25.0(CH or CH3),25.6(CH2),27.5(CH2),29.1(CH2),32.2(CH2),32.4(CH2),34.2(CH2),34.7(CH2),35.2(CH or CH3),38.3(CH2),41.0(q uart.C),44.0(quart.C),49.3(CH or CH3),52.8(CH or CH3),55.0(CH or CH3),58.2(quart.C),58.4(quart.C),64.7(CH or CH3,65.4(quart.C),67.1(C(3)H),128.7(C(6)H or C(7)H or C(24)H),135.5(C(6)H or C(7)H or C(24)H),147.6(CO),150.2(CO)
[0190] LC-MS(ES)m / z:
[0191] 526[M + +H],508[M + +H-H2O],380[M + +2H-H2O-dienophile],379[M + +1H-H2O-dienophile
[0192] EP-DAA-IP
[0193] 1 H-NMR (300MHz, CDCl3): δ (ppm):
[0194] 0.78(s,3H,C(18)H3),0.92(s,3H,CH3)0.95(d,3H,J=6.40Hz,C(21)H3),1.00-1 .35(m,4H),1.27(s,3H,CH3),1.31(s,3H,CH3),1.39(d,6H,J=6.59Hz,NCH(CH3) 2),1.45–2.12(m,16H),2.25(dd,1H,J=6.50Hz,12.15Hz,C(9)H),2.54(m,1H,C( 4)H2),2.69(br.t,J=4.33,6.03Hz,1H,C(24)H),3.12(dd,1H,J=3.58Hz,13.75Hz C(4)H2), 4.21(spt,1H,J=6.94Hz,NCH), 4.41(tt,1H,J=10.50,5.32Hz,C(3)H), 6.14(d,1H,J=8.29Hz,C(6)H or C(7)H), 6.32(d,1H,J=8.29Hz,C(6)H or C(7)H
[0195] 13 C-NMR (75MHz,CDCl3):δ(ppm):
[0196] 13.0(CH or CH3),17.6(CH or CH3),18.7(CH or CH3),18.8(CH or CH3),19.0(CH or CH3),19.8(CH or CH3),25.0(CH or CH3),25.5(CH2),25.6(CH2),27.5(CH2),29.1(CH2),32.2(CH2),32.4(CH2),34.2(CH2),34.7(CH2),35.2(CH or CH3),38.2(CH2),41.1(quart.C ),44.0(quart.C),49.3(CH or CH3),52.8(CH or CH3),55.0(CH or CH3),58.2(quart.C),58.4(quart.C),64.7(CH or CH3),64.9(CH or CH3),65.4(quart.C),67.3(C(3)H),128.7(C(6)H or C(7)H or C(24)H),135.4(C(6)H or C(7)H or C(24)H),147.5(CO),150.2(CO).
[0197] LC-MS(ES)m / z:
[0198] 541[M + +2H],540[M + +1H],523[M + +2H-H2O],397[M + +1H-dienophile]380[M + +2H-H2O-dienophile],379[M + +1H-H2O-dienophile
[0199] Diels-type reaction of cholesta-5,7,24-trien-3-ol and 4,4-diethylpyrazolidine-3,5-dione (EP-DAA-DP1) Epoxidation of Alder adducts
[0200] The Diels-Alder adduct of cholesta-5,7,24-trien-3-ol and 4,4-diethylpyrazolidine-3,5-dione (DAA-DP1) prepared as described above (1.11 g, 1.5 mmol) was added to a 100 ml flask along with toluene (25 ml). 3-Chlorobenzene peroxy acid (0.74 g, 3 mmol) was dissolved in toluene (15 ml) and added slowly to the reaction mixture to keep the temperature below 25°C. The reaction mixture was stirred at 23°C for 1 h. Afterwards, the reaction mixture was heated to 50°C and stirred for 1 h.
[0201] The reaction mixture was extracted with saturated aqueous sodium bicarbonate solution (2 x 50 ml). The organic phase was dried over Na2SO4, filtered and all volatiles were removed in vacuo. The epoxidized Diels-Alder adduct (EP-DAA-DP1) was prepared by 1 H-NMR, 13 C-NMR and LC-MS Characterization:
[0202] 1 H-NMR (300MHz, CDCl3): δ (ppm):
[0203] 0.67(t,3H,J=7.35,7.53Hz,CH2CH3),0.79(s,3H,C(18)H3),0.88(t,3H,J=7.35, 7.53Hz,CH2CH3),0.93(s,3H,CH3),0.95(d,3H,J=6.40Hz,C(21)H3),1.09-1.23(m , 1H), 1.26 (s, 3H, CH3), 1.31 (s, 3H, CH3), 1.32–2.16 (m, 19H), 2.30 (m, C(9)H), 2.59 (m, 1H, C(4)H2), 2.68 (m, C(24)H), 3.22 (dd, 1H, J = 3.77, 3.96 Hz, 13.75, 13.94 Hz C(4)H2), 4.36 (m, 1H, C(3)H), 6.18 (d, 1H, J = 8.29 Hz, C(6)H or C(7)H), 6.33 (d, 1H, J = 8.48 Hz, C(6)H or C(7)H);
[0204] 13 C-NMR (75MHz, CDCl3): δ (ppm):
[0205] 8.9(CH2CH3),9.7(CH2CH3),12.8(CH or CH3),17.5(CH or CH3),18.9(CH or CH3),22.5(CH2),23.7(CH2),25.0(CH or CH3),25.4(CH2),25.5(CH2),27.5(CH2),28.7(CH2),29.9(CH2),32.2(quart.C),32.4(CH2),34.3(CH2),34.9(CH2),35.2(CH or CH3),38.3 (CH2), 41.1 (quart. C), 43.9 (quart. C), 49.0 (CH or CH3), 52.9 (CH or CH3), 55.2 (CH or CH3), 58.5 (COCCO), 64.7 (CH or CH3), 64.6 (quart. C), 64.9 (CH or CH3) 65.9 (quart. C), 67.8 (C (3) H), 128.8 (C (6) H or C (7) H), 135.9 (C (6) H or C (7) H), 164.7 (CO), 168.9 (CO).
[0206] LC-MS(ES)m / z:
[0207] 553[M + +H],380[M + -2H-H2O-dienophile],379[M + -3H-H2O-dienophile].
[0208] Experimental part D: Synthesis of 25-hydroxy-7-dehydrocholesterol (=HyDHC).
[0209] General Procedures for Using EP-DAA-M, EP-DAA-E, and EP-DAA-IP
[0210] 1.7 mmol of the epoxidized Diels-Alder adduct of Table 3 prepared as described above was charged into a flask and dissolved in THF (18 ml) and toluene (4 ml). A 2.5 M solution of LiAlH4 in THF (24 ml, 67 mmol) was slowly added. The reaction mixture was then refluxed for 4 h and subsequently stirred at 60°C for 16 h. After the reaction mixture was cooled to 23°C, water (20 ml) was slowly added and the reaction mixture was stirred for 30 min. Celite (3.5 g) was added and the reaction mixture was stirred at 23°C for 3 h and then filtered. The filter cake was washed with THF (4×10 ml). The mother liquor was concentrated in vacuo. The residue was 25-hydroxy-7-dehydrocholesterol with the yield shown in Table 3.
[0211] The epoxidized Diels-Alder adduct used Yield [%] EP-DAA-M 99 EP-DAA-E 99 EP-DAA-IP 99
[0212] Table 3. Preparation of 25-hydroxy-7-dehydrocholesterol by reduction of epoxidized Diels-Alder adducts.
[0213] Reduction of EP-DAA-P1
[0214] The epoxidized Diels-Alder adduct (EP-DAA-DP1) prepared as described above (0.877 g, 1.5 mmol) was charged into a flask and dissolved in THF (36 ml). A 2M LiAlH4 solution in THF (3 ml, 6 mmol) was slowly added. The reaction mixture was then refluxed for 30 min. After the reaction mixture was cooled to 30° C., a saturated aqueous ammonium chloride solution (50 ml) was slowly added. Ethyl acetate (150 ml) was added and the phases were separated. The aqueous phase was extracted with ethyl acetate (50 ml). The combined organic phases were extracted with a saturated aqueous sodium chloride solution (50 ml). The organic phase was dried over Na2SO4, filtered and all volatiles were removed in vacuo. 25-Hydroxy-7-dehydrocholesterol (0.82 g, 33%) was isolated in a 45% total yield (including epoxidation and reduction).
[0215] It has been found that if 25-hydroxy-7-dehydrocholesterol is prepared from EP-DAA-M or EP-DAA-E or EP-DAA-IP or EP-DAA-DP1, they are identical independently (NMR and MS).
Claims
1. Compounds of formula (I) It is characterized in that X stands for NR 1 , where R 1 represents methyl or ethyl or propyl or butyl; and R represents H or an acyl group.
2. A compound of formula (I) according to claim 1, It is characterized in that R stands for H.
3. A compound of formula (I) according to claim 1 or 2, It is characterized in that X=NR 1 , where R 1 It represents methyl, ethyl or isopropyl.
4. A compound of formula (I) according to claim 1, It is characterized in that The acyl group is acetyl or benzoyl.
5. A method for preparing a compound of formula (I) by reacting a compound of formula (XI) with a compound of formula (XII) It is characterized in that X stands for NR 1 , where R 1 represents a methyl or ethyl or propyl or butyl group; and R represents H or an acyl group.
6. The method according to claim 5, Features R stands for H.
7. A method according to claim 5 or 6, Features X=NR 1 , where R 1 It represents methyl, ethyl or isopropyl.
8. The method according to claim 5, It is characterized in that The acyl group is acetyl or benzoyl.
9. The method according to claim 5 or 6, It is characterized in that The compound of formula (XII) is prepared by oxidizing the compound of formula (XIII) or a salt thereof with the compound of formula (XIV).
10. A method for preparing a compound of formula (II) Comprising the reaction step a) a) epoxidizing the compound of formula (I) by an epoxidizing agent It is characterized in that X stands for NR 1 , where R 1 represents a methyl or ethyl or propyl or butyl group; and R represents H or an acyl group.
11. The method according to claim 10, It is characterized in that R stands for H.
12. A method according to claim 10 or 11, It is characterized in that Prior to step a), a process for preparing a compound of formula (I) according to any one of claims 5 to 9 is carried out to provide a compound of formula (I).
13. Compounds of formula (II) It is characterized in that X stands for NR 1 , where R 1 represents a methyl or ethyl or propyl or butyl group; and R represents H or an acyl group.
14. A compound of formula (II) according to claim 13, It is characterized in that X=NR 1 , where R 1 It represents methyl, ethyl or isopropyl.
15. A compound of formula (II) according to any one of the preceding claims 13 to 14, It is characterized in that The acyl group is acetyl or benzoyl.
16. A method for preparing a compound of formula (III) comprising reaction step b) b) reducing the compound of formula (II) with a reducing agent to obtain a compound of formula (III) It is characterized in that X stands for NR 1 , where R 1 represents a methyl or ethyl or propyl or butyl group; and R represents H or an acyl group.
17. The method according to claim 16, It is characterized in that R stands for H.
18. A method according to claim 16 or 17, It is characterized in that Prior to step b), a process for preparing a compound of formula (II) according to any one of claims 10 to 12 is performed to provide said compound of formula (II).
